Terman BI, Doughervermazen M: Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev. 1996, 15: 159-163. 10.1007/BF00437468.
Article
CAS
PubMed
Google Scholar
Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR: Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol. 2007, 18: 1293-1306. 10.1093/annonc/mdm013.
Article
PubMed
Google Scholar
Ravdin PM: Docetaxel (Taxotere) for the treatment of anthra-cycline-resistant breast cancer. Semin Oncol. 1997, 24: 18-21.
Google Scholar
Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD: Phase I and pharmacokinetic study of Al-850, a novel microparticle hydrophobic drug delivery system for paclitaxel. Clin Cancer Res. 2007, 13: 3293-3301. 10.1158/1078-0432.CCR-06-2496.
Article
CAS
PubMed
Google Scholar
Lønning PE: Dose response evaluation – use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clin Pharmacokinet. 1993, 25: 1-5.
Article
PubMed
Google Scholar
Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR: Why hypertensive patients vary in their response to oral debrisoquine. Br Med J. 1977, 1: 422-425.
Article
CAS
PubMed
PubMed Central
Google Scholar
Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980, 17: 102-105. 10.1136/jmg.17.2.102.
Article
CAS
PubMed
PubMed Central
Google Scholar
Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001, 52: 349-355. 10.1046/j.0306-5251.2001.01499.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lønning PE, Kvinnsland S: Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs. 1988, 35: 685-710.
Article
PubMed
Google Scholar
Lønning PE, Schanche JS, Kvinnsland S, Ueland PM: Single-dose and steady-state pharmacokinetics of aminoglutethimide. Clin Pharmacokinet. 1985, 10: 353-364.
Article
PubMed
Google Scholar
Lønning PE: Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol. 2006, 17: 217-225. 10.1093/annonc/mdj048.
Article
PubMed
Google Scholar
Norum J, Olsen JA, Wist EA, Lonning PE: Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica. 2007, 46: 153-164. 10.1080/02841860601096841.
Article
CAS
PubMed
Google Scholar
Lønning PE, Skulstad P, Sunde A, Thorsen T: Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J Steroid Biochem. 1989, 32: 91-97. 10.1016/0022-4731(89)90019-8.
Article
PubMed
Google Scholar
Jacobs S, Lønning PE, Haynes B, Griggs L, Dowsett M: Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhibition. 1991, 4: 315-325. 10.3109/14756369109030396.
Article
CAS
Google Scholar
Lønning PE: Pharmacology of new aromatase inhibitors. Breast. 1996, 5: 202-208. 10.1016/S0960-9776(96)90094-6.
Article
Google Scholar
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lønning PE: Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer. 1996, 74: 1286-1291.
Article
CAS
PubMed
PubMed Central
Google Scholar
Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P, Droloxifene 301 Study Group: Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Br Cancer Res Treat. 2002, 73: 161-175. 10.1023/A:1015229630260.
Article
CAS
Google Scholar
Bruning PF: Droloxifene, a new anti-oestrogen in post-menopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer. 1992, 28A: 1404-1407. 10.1016/0959-8049(92)90530-F.
Article
CAS
PubMed
Google Scholar
Helle SI, Anker G, Tally M, Hall K, Lønning PE: Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol. 1996, 57: 167-171. 10.1016/0960-0760(95)00257-X.
Article
CAS
PubMed
Google Scholar
Lønning PE, Hall K, Aakvaag A, Lien EA: Influence of tamoxifen on the plasma levels of insulin-like growth factor I and Insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992, 52: 4719-4723.
PubMed
Google Scholar
Helle SI, Holly JMP, Tally M, Hall K, Stappen Jvd, Lønning PE: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer (Pred Oncol). 1996, 69: 335-339. 10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4.
Article
CAS
Google Scholar
Geisler J, Ekse D, Hösch S, Lønning PE: Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1995, 55: 193-195. 10.1016/0960-0760(95)00163-T.
Article
CAS
PubMed
Google Scholar
Geisler J, Haarstad H, Gundersen S, Raabe N, Kvinnsland S, Lønning PE: Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol. 1995, 146: 359-363. 10.1677/joe.0.1460359.
Article
CAS
PubMed
Google Scholar
Lønning PE: Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance. Trends Mol Med. 2004, 10: 113-118. 10.1016/j.molmed.2004.01.005.
Article
PubMed
Google Scholar
Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001, 61: 2505-2512.
CAS
PubMed
Google Scholar
Lønning P: Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol. 2003, 4: 177-185. 10.1016/S1470-2045(03)01022-2.
Article
PubMed
Google Scholar
Staalesen V, Leirvaag B, Lillehaug JR, Lønning PE: Genetic and epigenetic changes in p21 and p21B do not correlate to resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clin Cancer Res. 2004, 10: 3438-3443. 10.1158/1078-0432.CCR-03-0796.
Article
CAS
PubMed
Google Scholar
Knappskog S, Chrisanthar R, Staalesen V, Børresen-Dale AL, Gram IT, Lillehaug JR, Lønning PE: Mutations and polymorphisms of the p21B transcript in breast cancer. Int J Cancer. 2007, 121: 908-910. 10.1002/ijc.22777.
Article
CAS
PubMed
Google Scholar
Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006, 6: 909-923. 10.1038/nrc2012.
Article
CAS
PubMed
Google Scholar
Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989, 49: 2175-2183.
CAS
PubMed
Google Scholar
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN: Pharmacogenetics of tamoxifen biotrans-formation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23: 9312-9318. 10.1200/JCO.2005.03.3266.
Article
CAS
PubMed
Google Scholar
Hayes DF, Steams V, Rae J, Flockhart D: A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?. J Nat Cancer Instit. 2008, 100: 610-613. 10.1093/jnci/djn127.
Article
Google Scholar
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE: CHEK2 mutations affecting kinase activity together with mutations in the TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 2008, 3: e3062-10.1371/journal.pone.0003062.
Article
PubMed
PubMed Central
Google Scholar
Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lønning PE: TP53 gene mutations predict the response to neoadjuvant treatment with FUMI in locally advanced breast cancer. Clin Cancer Res. 2003, 9: 5582-5588.
CAS
PubMed
Google Scholar
Staalesen V, Falck J, Geisler S, Bartkova J, Børresen-Dale AL, Lukas J, Lillehaug JR, Bartek J, Lønning PE: Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene. 2004, 23: 8535-8544. 10.1038/sj.onc.1207928.
Article
CAS
PubMed
Google Scholar